Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma
NCT03463408 · Status: ACTIVE_NOT_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 14
Last updated 2025-08-11
Summary
Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma
Conditions
- Sarcoma
Interventions
- DRUG
-
240 mg every 2 weeks
- DRUG
-
1 mg/kg every 6 weeks
Sponsors & Collaborators
-
University of Rochester
lead OTHER
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-07-17
- Primary Completion
- 2026-08-01
- Completion
- 2026-08-01
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma
NCT04356872 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors
NCT03192943 ·Status: COMPLETED ·Phase: PHASE1
-
The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma
NCT05774275 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of a Third-Course of Neoadjuvant Immunochemotherapy Combined With SBRT in Locally Advanced Head and Neck Squamous Cell Carcinoma Patients With Stable Disease After Two Treatment Courses: A Single-Arm Exploratory Study
NCT06722495 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Neoadjuvant Radiotherapy Combined With Toripalimab for Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT05861557 ·Status: UNKNOWN ·Phase: PHASE2
-
Anlotinib and Radiotherapy in Resectable Soft Tissue Sarcoma
NCT05602415 ·Status: UNKNOWN ·Phase: PHASE2
-
An Expanded Clinical Study of Triple Therapy for Refractory Solid Tumors That Failed First-line Treatment for Recurrence and Metastasis
NCT05438342 ·Status: UNKNOWN ·Phase: NA
-
A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors
NCT05134948 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma
NCT03217266 ·Status: COMPLETED ·Phase: PHASE1
-
Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers
NCT03749460 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma
NCT04143984 ·Status: RECRUITING ·Phase: PHASE2
-
RT-01 Monotherapy and in Combination With Nivolumab in Patients With Advanced Solid Tumors
NCT05122572 ·Status: UNKNOWN ·Phase: PHASE1
-
Cadonilimab in the Treatment of Advanced Soft Tissue Sarcoma
NCT05656144 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Relatlimab in Combination With Nivolumab in Chinese Participants
NCT05498480 ·Status: COMPLETED ·Phase: PHASE1
-
Neoadjuvant Treatment For Locally Advanced Thymic Cancer
NCT06019468 ·Status: RECRUITING ·Phase: PHASE2
-
Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma
NCT03984357 ·Status: COMPLETED ·Phase: PHASE2
-
To Explore the Effect of Immune-induced Stereotactic Body Radiotherapy (SBRT) on Reversing Immunoresistance in Stage IIIc/IV Non-small Cell Lung Cancer (NSCLC)
NCT06154967 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC
NCT06345287 ·Status: RECRUITING ·Phase: PHASE2
-
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Soft Tissue Sarcomas
NCT06644287 ·Status: RECRUITING
-
Toripalimab Combined With CAV/IE Regimen
NCT04589741 ·Status: RECRUITING ·Phase: PHASE2
-
SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx
NCT06611137 ·Status: RECRUITING ·Phase: PHASE2
-
PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)
NCT06074692 ·Status: RECRUITING ·Phase: PHASE2
-
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors
NCT05572684 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Prospective Clinical Cohort Study on Stratified Treatment of Rhabdomyosarcoma Based on Risk Factors.
NCT06836492 ·Status: RECRUITING ·Phase: PHASE3
-
Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma
NCT06673693 ·Status: RECRUITING ·Phase: PHASE2